Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, Peter Lynch
Search This Board: 
Last Post: 8/22/2017 7:13:57 PM - Followers: 125 - Board type: Free - Posts Today: 18
* shareholders, please consider purchasing product(s)


Awaiting Official Announcement of FDA Approval for FlutiCare

FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.


The CEO has already signed an agreement for the manufacturing of FlutiCare

Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.


Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)


Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.

Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.

Bassam Damaj, Ph.D.
President and Chief Executive Officer:

Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.

Who are the major players at Innovus Pharma?


Share Structure:

Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 


Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call

Corporate Presentation November 2016 (8-K  11/1/2016)

Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)

Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products

Major 2016 Accomplishments:



Where can INNV products be seen?


Existing Product Lines @ Innovus Pharma:

Newest Product:


PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


Are you looking to boost your brain health?r

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV News: Quarterly Report (10-q) 08/14/2017 04:43:27 PM
INNV News: Current Report Filing (8-k) 08/14/2017 04:35:16 PM
INNV News: Small Company Offering and Sale of Securities Without Registration (d) 08/02/2017 06:07:19 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 07/03/2017 06:13:38 AM
INNV News: Statement of Changes in Beneficial Ownership (4) 07/03/2017 06:12:24 AM
#11037  Sticky Note Innovus Pharma Orders its First Commercial Batch of kkpennies 08/09/17 02:44:19 PM
#10696  Sticky Note $INNV Improving. We can handle it. Figure BooDog 07/21/17 05:45:08 AM
#11363   They can say whatever they want in a twistedfreak 08/22/17 07:02:20 PM
#11361   SeeThroughEquity is a paid-for infomercial. Nothing more. Next? twistedfreak 08/22/17 06:56:32 PM
#11360   See Thru Equity today mulally 08/22/17 06:46:21 PM
#11359   I am with Scottrade and I cannot short twistedfreak 08/22/17 06:31:46 PM
#11358   Wwwhat?? You can't short OTC stocks?? That is jtaylor68 08/22/17 05:57:37 PM
#11355   Now why the name calling mulally? I am twistedfreak 08/22/17 04:49:25 PM
#11354   You have no rationale. The speculation mulally 08/22/17 04:21:17 PM
#11353   I contend that INNV will be 20% less twistedfreak 08/22/17 03:42:35 PM
#11352   But now is the time for people to mulally 08/22/17 11:42:16 AM
#11351   2 1/2 to 3 quarters away. It may twistedfreak 08/22/17 11:41:30 AM
#11350   I wouldn't be so sure. Undervalued as mulally 08/22/17 10:52:27 AM
#11349   the market has pinned a very realistic value twistedfreak 08/22/17 10:06:39 AM
#11348   Not a more undervalued penny on the market mulally 08/22/17 09:41:48 AM
#11347   Clev3land, how many FDA decades, dilutions and reverse gi197845 08/21/17 03:23:12 PM
#11346   "Although Innovus is actively working to put the twistedfreak 08/21/17 10:37:03 AM
#11345   The new article that came out that was Clev3land 08/21/17 09:31:57 AM
#11344   approaching $50,000,000 deficit TrueTrades 08/19/17 06:32:21 PM
#11343   ShawnP123, I'm pretty sure the Fluticare ANDA will gi197845 08/19/17 01:14:23 PM
#11342   TF- People think just because someone filed for ShawnP123 08/19/17 11:11:41 AM
#11341   there is no reason for an ANDA twistedfreak 08/19/17 07:34:33 AM
#11340   If that ANDA was flawed, INNV would have jtaylor68 08/18/17 05:39:18 PM
#11339   Hurling insults? Because I wrote "pestering", the same jtaylor68 08/18/17 05:30:23 PM
#11338   Sure they will or already do. From the jtaylor68 08/18/17 05:13:44 PM
#11337   gi197845, you are delusional. The FDA does not twistedfreak 08/18/17 05:02:24 PM
#11336   There you go, hurling insults. Your YMB message twistedfreak 08/18/17 04:58:21 PM
#11335   The announcement of the Fluticare launch in Q4 gi197845 08/18/17 04:06:29 PM
#11334   Jtaylor68, do you think INNV will ever advertise gi197845 08/18/17 03:56:45 PM
#11333   Some people have other important things to do jtaylor68 08/18/17 03:35:04 PM
#11332   This is definitely not a fluff piece compared jtaylor68 08/18/17 03:22:22 PM
#11331   I'm curious where Honeycomb is. He was very twistedfreak 08/18/17 10:57:30 AM
#11330   Good to see that our writer is back BooDog 08/18/17 10:03:31 AM
#11329   Yes, it's a known since the Hikma deal twistedfreak 08/18/17 07:59:04 AM
#11328   "We are very excited about the upcoming commercial Gigi70 08/18/17 07:26:32 AM
#11327   This is not news. This is a regurgitated twistedfreak 08/18/17 07:10:44 AM
#11326   News!! Innovus Pharma CEO Details FlutiCare Stacking goods 08/18/17 06:48:58 AM
#11325   Hit it, quit it, park stop it, neutral gi197845 08/17/17 09:36:51 PM
#11324   Clev3land, that's because Dr.Damaj is slathering on the gi197845 08/17/17 05:36:04 PM
#11323   He is slick. That's what I like about Clev3land 08/17/17 08:26:55 AM
#11322   What happened before at another company..who really cares. Clev3land 08/17/17 08:24:35 AM
#11321   I'm not gone. I'm stating I will wait ShawnP123 08/17/17 07:29:54 AM
#11320   I disagree with the last point. Looks like sweetstreet 08/16/17 10:52:58 PM
#11319   Read again what I wrote in #11307 and jtaylor68 08/16/17 10:17:08 PM
#11318   closing arguments are done TrueTrades 08/16/17 09:32:38 PM
#11317   Amazing how most of the arguing has stopped gi197845 08/16/17 09:13:23 PM
#11316   Are you drunk? The same share price appreciation twistedfreak 08/16/17 08:45:53 PM
#11315   He did not increase the APRI share price twistedfreak 08/16/17 08:42:07 PM
#11314   Well, you brought up the "Contigent Consideration" and jtaylor68 08/16/17 08:30:26 PM
#11313   Taylor, this is just boring now. I am twistedfreak 08/16/17 07:48:56 PM
#11312   TF, please not these old accusations again. Why jtaylor68 08/16/17 04:35:37 PM
#11311   yep, the "short lived spike' is called a twistedfreak 08/15/17 07:11:17 PM